Mark Eisner: Yeah, so I’ll try to address both of your questions. So the second part first. Yeah, I think these endpoints are going to be more challenging in the non-ambulatory population and the ambulatory. What will say that the cardiac MRI is not nearly the same relevance for the younger patients who are aged 6 to 12, because that’s a relatively – cardiac manifestations are relatively later manifestation in the disease. So that for ambulatory, it’s the North Star, it’s stair climb, it’s 10 meter walk. Other endpoints like that are the primary and secondary endpoints. So, ultimately, the North Star, I think has been quite well, looked out and in the setting of other studies and we expect that it’s a validated endpoint, and we’re looking forward to those results.
Annabel Samimy : Okay. Sorry. And is there any avenues for you to file – secondary benefits because of the North Star?
Mark Eisner: Well, so I think your question is for example, the North Star is kind of a near miss in their secondary endpoints. They are positive. So in that case, potentially, I mean, any positive data that we see in the ambulatory trial, I think would be the basis for us to want to really explore regulatory pathways with the FDA. So it’ll be a data-driven decision, but we of course will look at all the endpoints and really look for any signs of efficacy in that trial that’s coming up.
Annabel Samimy : Okay. And then, if I can ask one more question with regard to pirfenidone is an anti-fibrotic agent, are there any other markers that you looked at from the LELANTOS-1 trial to give you an idea that there is actually anti fibrotic activity And, I couldn’t help but sense the confidence about just, going into this trial. And so I’m just wondering if you saw anything else that that gave you some help.
Mark Eisner: Unfortunately, the LELANTOS-1 was really, there was no endpoint that really showed any signs of efficacy. It may be due to the non-ambulatory population and how advanced it is. I think the ambulatory LELANTOS-2 trial data will really help us to answer what clinical benefit and otherwise can be shown and DMD. So I think the studies will together tell the full story. So we have half the answer and we’re eagerly awaiting the rest of the information from LELANTOS-2.
Annabel Samimy : Okay. Great. Thank you.
Mark Eisner: Thank you for the questions.
Operator: One moment for our next question. Our next question comes from the line of Alexandra Ramsey from William Blair. Please proceed with your question.
Alexandra Ramsey: Hello. This is Alex Ramsey on from William Blair. So a couple of questions from us if you don’t mind. So, the first question is about the term loan with Morgan Stanley Tactical value? We’re just curious about the status of the $75 million initial term loan. And is there any plan to pay back that loan earlier than the May 2026 maturation date or if that’s dictated by the terms of the loan? And then, second Mark, we were curious to hear if you have any insights on the ZEPHYRUS data. And if you have – in terms of why it underperformed for pamrevlumab and we’d understand that you’re probably early in analysis. We’re just wondering if anything popped out during the initial analysis. Thanks so much.
Thane Wettig: Yes. Thanks Alex. I’ll have Juan address the MSTV question and then turn it over to Mark.
Juan Graham: Yeah, Alex. Yes, on the term loan as you pointed out, we have an initial draw of $75 million. That has actually occurred as of the beginning of May, May 8th. I believe it was we received $75 million. So that’s what we would expect to hold on until term maturity at this point in time. There’s no plan for early repayment.
Thane Wettig: Thanks, Juan. Mark?
